Revolution Medicines, Inc.

NASDAQ:RVMD

Biotechnology

Healthcare
$159.82 +2.28%

+$3.60 today

Market cap
$34.57B
Beta
1.41
P/E (TTM)
-23.3
EPS (TTM)
-$6.92
52W Low $34.00High $166.50

Volume 2.34M

Average 3.10M

RVMD Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Revolution Medicines, Inc.NASDAQ: RVMD

Gross Profit · Q2 FY2026 · quarter ended Jun 2026

Gross profit remains negative

Q2 FY2026 gross profit was $0, compared with $0 a year earlier. Trailing-twelve-month gross profit was -$9.24M.

Context

  • Gross profit increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$2.31M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0+100.0% QoQ
Last fiscal yearDec 2025
-$16.56M— YoY
LTMJun 2026
-$9.24M— YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
(16.56M) USD
Year-over-year change
—

Gross Profit vs competitors

How RVMD compares with its peers on the latest reported figures

  • RVMD's LTM Jun 2026 gross profit of -$9.24M is the 9th highest of the 11 companies compared; the peer median is -$216.5K.
RVMD Competitors Peer median
Gross Profit for RVMD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$607.18M +545.5%—86.5%
VSTMVerastem, Inc.LTM Mar 2026$41.53M +315.3%+114.5%83.7%
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026$40.92M -74.0%—95.3%
ELVNEnliven Therapeutics, Inc.LTM Sep 2026-$60K ———
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 2026-$113K -100.2%——
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026-$320K -5.3%——
TNGXTango Therapeutics, Inc.LTM Sep 2026-$942K -101.4%+34.2%—
ERASErasca, Inc.LTM Sep 2026-$1.47M -76.2%——
RVMDRevolution Medicines, Inc.LTM Jun 2026-$9.24M ———
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026-$19.69M +70.5%+63.7%8.7%
RLAYRelay Therapeutics, Inc.LTM Jun 2026-$58.64M +69.8%—566.6%
Peer median (excluding RVMD) -$216.5K-5.3%+63.7%86.5%

Competitors are the stored peer set for RVMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue29.39M35.38M11.58M00
Cost of Revenue000016.56M
Gross Profit29.39M35.38M11.58M0(16.56M)
Gross Margin100.0%100.0%100.0%——
Research & Development186.95M253.07M423.14M592.23M978.68M
Selling, General & Admin30.45M40.59M75.62M97.3M187.13M
Operating Expenses217.4M293.66M498.77M689.52M1.17B
Depreciation & Amortization7.33M9.66M9.31M11.82M16.56M
EBITDA(179.75M)(239.47M)(430.28M)(589.02M)(1.09B)
EBITDA Margin-611.6%-676.8%-3715.7%——
Operating Income(188.01M)(258.28M)(487.19M)(689.52M)(1.18B)
Operating Margin-639.7%-730.0%-4207.1%——
Interest Income929K9.15M47.48M86.88M90.69M
Interest Expense12K0303K024.23M
Other Income / Expenses917K9.15M47.29M88.68M51.07M
Income Before Tax(187.09M)(249.13M)(439.89M)(600.85M)(1.13B)
Pre-Tax Margin-636.6%-704.1%-3798.7%——
Income Tax Expense0(420K)(3.52M)(753K)0
Net Income(187.09M)(248.71M)(436.37M)(600.09M)(1.13B)
Net Margin-636.6%-703.0%-3768.3%——
EPS (Basic)(2.47)(3.08)(3.86)(3.58)(5.95)
EPS (Diluted)(2.47)(3.08)(3.86)(3.58)(5.95)
Weighted Avg Shares72.81M80.63M113.15M167.74M190.13M
Weighted Avg Shares (Diluted)72.81M80.63M113.15M167.74M190.13M

Revolution Medicines, Inc.

NASDAQ:RVMD

Intrinsic Alpha fair value

Locked

Current Price

$159.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.